LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

MacroGenics Inc

Затворен

СекторЗдравеопазване

1.57 -2.48

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.55

Максимум

1.58

Ключови измерители

By Trading Economics

Приходи

-26M

-41M

Продажби

-4.5M

13M

Марж на печалбата

-311.067

Служители

341

EBITDA

-27M

-39M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+129.75% upside

Дивиденти

By Dow Jones

Следващи печалби

18.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-61M

93M

Предишно отваряне

4.05

Предишно затваряне

1.57

Настроения в новините

By Acuity

50%

50%

157 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.08.2025 г., 16:11 ч. UTC

Значими двигатели на пазара

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15.08.2025 г., 22:22 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

15.08.2025 г., 22:22 ч. UTC

Пазарно говорене

Target Is Falling Behind Its Peers -- Market Talk

15.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.08.2025 г., 20:33 ч. UTC

Пазарно говорене

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15.08.2025 г., 20:25 ч. UTC

Печалби
Придобивния, сливания и поглъщания

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15.08.2025 г., 20:24 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15.08.2025 г., 20:18 ч. UTC

Печалби

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15.08.2025 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15.08.2025 г., 19:12 ч. UTC

Пазарно говорене

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15.08.2025 г., 18:32 ч. UTC

Пазарно говорене

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15.08.2025 г., 17:33 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15.08.2025 г., 17:23 ч. UTC

Пазарно говорене
Печалби

Deere's Earnings Appear to Be Troughing -- Market Talk

15.08.2025 г., 16:27 ч. UTC

Печалби

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.08.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

15.08.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15.08.2025 г., 15:52 ч. UTC

Придобивния, сливания и поглъщания

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15.08.2025 г., 15:36 ч. UTC

Пазарно говорене

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15.08.2025 г., 15:29 ч. UTC

Печалби

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15.08.2025 г., 15:29 ч. UTC

Придобивния, сливания и поглъщания

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15.08.2025 г., 15:28 ч. UTC

Печалби

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15.08.2025 г., 15:24 ч. UTC

Пазарно говорене

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15.08.2025 г., 15:08 ч. UTC

Пазарно говорене

Applied Materials Is Losing Share in Chips Business -- Market Talk

15.08.2025 г., 14:38 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15.08.2025 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15.08.2025 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15.08.2025 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15.08.2025 г., 14:33 ч. UTC

Придобивния, сливания и поглъщания

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

129.75% нагоре

12-месечна прогноза

Среден 3.63 USD  129.75%

Висок 5 USD

Нисък 1.5 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

6 ratings

1

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

157 / 374 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.